Showing 20 of 200 recruiting trials for “large-granular-lymphocyte-leukemia”
Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
👨⚕️ Caroline Diorio, MD, Children's Hospital of Philadelphia📍 1 site📅 Started Apr 2025View details ↗
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
👨⚕️ Yue-jun Liu, The First Affiliated Hospital of Soochow University📍 1 site📅 Started Apr 2025View details ↗
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
👨⚕️ Joseph McGuirk, D.O., University of Kansas Medical Center📍 1 site📅 Started Mar 2025View details ↗
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
👨⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
Newly-diagnosed Pediatric T-cell ALL Protocol
👨⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
RecruitingNCT06784167 ↗
Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
👨⚕️ Xiaofan Zhu, MD, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC📍 27 sites📅 Started Mar 2025View details ↗
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
👨⚕️ Xiangbo Wan, PhD., The First Affiliated Hospital of Zhengzhou University📍 1 site📅 Started Mar 2025View details ↗
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
64Cu-LLP2A for Imaging Hematologic Malignancies
👨⚕️ Farrokh Dehdashti, M.D., Washington University School of Medicine📍 1 site📅 Started Feb 2025View details ↗
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
RecruitingNCT06788639 ↗
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
RecruitingNCT06821880 ↗
Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID Project
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →